



Cochrane Database of Systematic Reviews
 
Minimally invasive treatments for lower urinary tract symptoms in
men with benign prostatic hyperplasia: a network meta-analysis
(Protocol)
 
  Franco JVA, Jung JH, Imamura M, Borofsky M, Omar MI, Escobar Liquitay CM, Young S, Veroniki
AA, Garegnani L, Dahm P
 
  Franco JVA, Jung JH, Imamura M, Borofsky M, Omar MI, Escobar Liquitay CM, Young S, Veroniki AA, Garegnani L, Dahm P. 
Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-
analysis (Protocol). 




Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a
network meta-analysis (Protocol)
 








Cochrane Database of Systematic Reviews












CONTRIBUTIONS OF AUTHORS................................................................................................................................................................... 21
DECLARATIONS OF INTEREST..................................................................................................................................................................... 21
SOURCES OF SUPPORT............................................................................................................................................................................... 22
NOTES........................................................................................................................................................................................................... 22
Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis
(Protocol)









Cochrane Database of Systematic Reviews
[Intervention Protocol]
Minimally invasive treatments for lower urinary tract symptoms in men
with benign prostatic hyperplasia: a network meta-analysis
Juan VA Franco1, Jae Hung Jung2, Mari Imamura3, Michael Borofsky4, Muhammad Imran Omar5,6, Camila Micaela Escobar Liquitay7,
Shamar Young8, Areti Angeliki Veroniki9, Luis Garegnani7, Philipp Dahm10
1Argentine Cochrane Centre, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina. 2Department of Urology, Yonsei University
Wonju College of Medicine, Wonju, Korea, South. 3Health Services Research Unit, University of Aberdeen, Aberdeen, UK. 4Department
of Urology, University of Minnesota, Minneapolis, Minnesota, USA. 5European Association of Urology, Arnhem, Netherlands. 6Academic
Urology Unit, University of Aberdeen, Aberdeen, UK. 7Research Department, Instituto Universitario Hospital Italiano, Buenos Aires,
Argentina. 8Department of Radiology, Division of Interventional Radiology, University of Minnesota, Minneapolis, Minnesota, USA.
9Department of Primary Education, School of Education, University of Ioannina, Ioannina, Greece. 10Urology Section, Minneapolis VA
Health Care System, Minneapolis, Minnesota, USA
Contact address: Juan VA Franco, juan.franco@hospitalitaliano.org.ar, jvaf85@gmail.com.
Editorial group: Cochrane Urology Group.
Publication status and date: New, published in Issue 6, 2020.
Citation: Franco JVA, Jung JH, Imamura M, Borofsky M, Omar MI, Escobar Liquitay CM, Young S, Veroniki AA, Garegnani L, Dahm P.
Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis
(Protocol). Cochrane Database of Systematic Reviews 2020, Issue 6. Art. No.: CD013656. DOI: 10.1002/14651858.CD013656.
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
Primary
To assess the comparative eFectiveness of minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic
hyperplasia.
Secondary
To obtain an estimate of relative ranking of these minimally invasive treatments according to their eFects.
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B A C K G R O U N D
Description of the condition
The prostate gland is an organ approximately the size of a walnut
that is located below the urinary bladder encircling the urethra
(Leissner 1979). Benign prostatic obstruction (BPO) is a form of
bladder outlet obstruction and may be diagnosed when the cause
of outlet obstruction is known to be benign prostatic enlargement
(BPE) due to benign prostatic hyperplasia (BPH); however, the
latter is restricted to the histological diagnosis defined as increased
numbers of epithelial and stromal cells in the prostate (Abrams
2003). BPH may or may not cause lower urinary tract symptoms
(LUTS), characterised by frequency, hesitancy, and a weak stream,
mainly  in men over the age of 40 years, and receives clinical
relevance when associated with perceived bother (Dunphy 2015).
Symptom bother typically correlates with increased number and
severity of symptoms, which are related to both quality of life
impairment and treatment seeking (Agarwal 2014). Although we
understand that LUTS is a functional unit with a multi-factorial
aetiology of associated symptoms, we considered the term BPH for
this Cochrane Review due to its familiarity to the general public
(EAU 2020).
The degree of bother across all LUTS can be assessed through self-
administered questionnaires, namely, the International Prostate
Symptom Score (IPSS; also known as the American Urological
Association (AUA) questionnaire), which includes the quality of
life domain (Barry 1995). Chapple 2017 reported that increasing
LUTS severity was associated with worsening men's overall distress
through patient perception of the bladder condition, which is a
single-item global question (with responses ranging from 1 (causes
no problems at all) to 6 (causes severe problems)).
Progression of LUTS has been observed in up to 31% of men
with BPH at seven-year follow-up (Emberton 2008). Progression to
acute urinary retention is less frequent and in men with moderate
symptoms can range from 3.0/1000 person-years in those aged
40 to 49 years to 34.7/1000 person-years in those aged 70 to 79
years (Emberton 2008). BPH also has a negative impact on public
health and reduces a person's quality of life (Kozminski 2015; Martin
2014). In Europe, 30% of men over 50 years of age, equivalent to 26
million men, are aFected by bothersome LUTS, including storage
symptoms (such as urinary frequency, urgency, and nocturia) or
voiding symptoms (such as urinary hesitancy, weak urinary stream,
straining to void, and prolonged voiding), or both. The yearly
reported associated number of medical prescriptions is estimated
to be around 11.6 million for 74 million people at risk from 2004
to 2008 (Cornu 2010). The prevalence of LUTS, according to an
international study involving 7588 men, was 18% during ages in the
40s, 29% in the 50s, 40% in the 60s, and 56% in the 70s (Homma
1997). More recent data show the lifetime prevalence of BPH as
26.2% (95% confidence interval (CI) 22.8% to 29.6%) (Lee 2017).
Diagnosis
Initial evaluation of LUTS suggestive of BPH includes patient
history, physical examination including a digital rectal examination
(DRE), urinalysis, a prostate-specific antigen (PSA) blood test if a
diagnosis of prostate cancer changes management, use of a voiding
diary, and IPSS (EAU 2020; McVary 2011). A DRE  is performed
to assess both nodules  suspicious for cancer and prostate size;
recently, additional imaging studies have been recommended for
patients considering surgical intervention (Foster 2019).
PSA is secreted by the prostate gland and is found to be abnormally
elevated in conditions such as prostate cancer, BPH, infection, or
inflammation of the prostate (EAU 2020; McVary 2011). The IPSS
is used to assess urinary symptom severity and quality of life.
It is also used to document subjective responses to treatment
(Barry 1992; EAU 2020; McVary 2011). Measurement of maximum
flow rate (Qmax) and postvoid residual (PVR) is oMen used in
diagnosis and treatment decisions (EAU 2020; McVary 2011). A
low Qmax and a large PVR predict increased risk of symptom
progression (Crawford 2006). Other tests such as radiological
imaging, urodynamic evaluation, and cystoscopy can help the
clinician determine appropriate treatment and predict treatment
response (Egan 2016; McVary 2011).
Treatment
Treatment decisions are based on symptoms and the degree of
symptom bother noted by the patient. Initial treatment options
for BPH include conservative management (watchful waiting and
lifestyle modification) and use of medications (alpha blockers, 5-
alpha reductase inhibitors, and, recently, phosphodiesterase
inhibitors) (EAU 2020; McVary 2011). When patients have been
refractory to conservative and medical treatment, or if BPH
causes subsequent complications, such as acute urinary retention,
recurrent urinary tract infection, bladder stones, haematuria, or
renal insuFiciency, surgical options are considered (EAU 2020;
McVary 2011).
Until the 1970s, the only option available to treat this
condition and relieve LUTS was open simple prostatectomy
(in very large prostates)  or endoscopic surgery in the form
of transurethral prostatectomy, with the aim of removing or
resecting prostatic tissue to open up the blocked urethra (Pariser
2015). Clinical guidelines continue to recommend monopolar
or bipolar transurethral resection of the prostate (TURP) as
a ('gold') reference standard  treatment  to provide subjective
symptom relief while attaining objective improvement in urinary
flow (Alexander 2019; EAU 2020; McVary 2011), but this procedure
is associated with some morbidity and long-term complications,
including haematuria possibly requiring a blood transfusion,
urethral stricture, urinary tract infection, and incontinence, and
it usually requires at least overnight hospitalisation.  Moreover,
men may experience ejaculatory (65%) and erectile dysfunction
(10%) related to TURP (Roehrborn 2003). Furthermore, BPH is a
disease that is common among elderly men, who have increased
preoperative risk for complications of  general anaesthesia and
surgery in general (Dunphy 2015; Yoo 2012).
Recently, several other minimally invasive treatments (MITs) that
can be performed in an oFice setting and do not require general
anaesthesia have been developed as alternatives to TURP (EAU
2020; McVary 2011), with the purpose of providing therapeutic
alternatives involving lower morbidity. However, most men who
consider surgical intervention do so with the expectation that this
is a more definitive therapy for LUTS that will preclude the need for
additional medical or surgical therapy. Given the relatively high rate
of reoperation or continued use of medical therapy aMer surgical
treatment (or both), concern has been raised about the durability
of newly launched minimal invasive surgeries (NICE 2015; Strope
2015).
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Description of the intervention
Minimally invasive treatments that can be performed in an oFice
setting and do not require general anaesthesia include convective
radiofrequency water vapour therapy (CRFWVT), prostatic arterial
embolisation (PAE), prostatic urethral liM (PUL), a temporary
implantable nitinol device (TIND), and transurethral microwave
therapy (TUMT).
Convective radiofrequency water vapour therapy
The Rezūm system (NxThera Inc., Maple Grove, MN, USA) uses
radiofrequency to create thermal energy in the form of water
vapour to ablate prostatic tissue (Woo 2017). This system consists
of two main components: a radiofrequency power supply generator
and a single-use transurethral delivery device that incorporates
a standard rigid cystoscope lens, which allows the procedure to
be performed under direct visualisation. Water vapour thermal
energy is generated by applying a radiofrequency current against
an inductive coil heater. The handheld control delivers water
vapour, providing a consistent energy dose of ~ 208 calories
into the prostate tissue through a retractable needle (Woo 2017).
Convective radiofrequency thermal therapy is performed with the
person in the dorsal lithotomy position using conscious sedation.
Cystoscopic examination is performed for confirmation of the
contours of the prostate and planned distribution of thermal
lesions (Darson 2017; Dixon 2015; Woo 2017). The treatment
needle is positioned for starting approximately 1 centimetre distal
from the bladder neck and targeting the transition and central
prostate adenoma by eye. Each injection of water vapour lasts
approximately 9 seconds. Additional injections of vapour are
delivered every 1 centimetre from the initial injection site of the
prostatic urethra to the proximal edge of the verumontanum. The
total number of injections in each lobe of the prostate is determined
by the length of the prostatic urethra and the configuration of
the prostate gland (Dixon 2015; Woo 2017). Saline flush irrigation
is used to enhance visualisation and to cool the urethral surface
(Woo 2017). Although most adverse events are transient and are
classified as Clavien-Dindo Grade I or II, a non-randomised pilot
study has reported 125 adverse events in 45 of 64 participants
(69.2%) (Dixon 2015). The most common adverse events are
postoperative urinary retention (33.8%), dysuria (21.5%), urinary
urgency (20%), and suspected urinary tract infection (20%). Twelve
serious adverse events were reported in 10 participants, one of
which was suspected to be a procedure-/device-related adverse
event (Clavien-Dindo Grade IIIb urinary retention) (Dixon 2015).
Prostatic arterial embolisation
Embolisation of the prostatic arteries has historically been used
to control persistent or massive prostatic bleeding not otherwise
amenable for treatment, with typical causes being BPH and
locally advanced prostate cancer, or it has been performed
aMer transurethral prostatectomy (Mitchell 1976). DeMeritt 2000
reported a case in which PAE was performed with polyvinyl
alcohol particles for BPH-induced haematuria, haematuria was
immediately stopped. and the patient reported symptomatic
improvement of his BPH symptoms. These researchers also
found that prostate size was reduced by 52% and 62% of the
initial size at 5-month and 12-month follow-up, respectively.
Carnevale 2010 reported positive preliminary results of PAE
procedures with microspheres as a primary treatment in two
patients with acute urinary retention due to BPH. For elderly
patients with symptomatic BPH, PAE can be an alternative
treatment performed by a femoral or radial artery puncture using
conscious sedation instead of general anaesthesia. This procedure
is typically performed on an outpatient basis and usually does
not require catheterisation, unless the patient is experiencing
urinary retention (Wang 2015). In preparation for PAE, preoperative
computed tomography or magnetic resonance angiography is
typically performed to evaluate the pelvic artery anatomy. Digital
subtraction angiography of the right and leM internal iliac arteries
is performed to assess the prostatic blood supply (Martins Pisco
2012). Super-selective microcatheterisation and embolisation are
then performed on the prostatic arteries. Embolisation is typically
performed to complete stasis (Carnevale 2010; Martins Pisco 2012;
Wang 2015). Cone beam computed tomography can be used not
only to help identify all prostatic arteries, but also to identify and
avoid embolisation of vessels feeding adjacent pelvic structures
(Wang 2015). Particle embolics are used almost exclusively, with
wide variation in the type and size of particles (Carnevale
2010; DeMeritt 2000). Vasodilators to mitigate vasospasm once
the prostatic artery is catheterised are also recommended by
some researchers to avoid premature stasis (Martins Pisco 2012).
Although the major complication rate is low (< 1%) (Pisco 2016),
perineal pain (9.4%), haematuria (9%), and acute urinary retention
(7%) are commonly reported as complications of PAE (Feng 2017).
The highest prevalence of acute urinary retention amongst the
included studies was 28.4% (Wang 2015). Minor complications,
such as hematospermia, rectal bleeding, urinary tract infection,
inguinal haematoma, and transient urinary frequency are also
reported (Feng 2017; Kuang 2017; Pyo 2017; Shim 2017). However,
there is inconsistency in reporting or classifying adverse events.
Prostatic urethral li5
Prostatic urethral liM (PUL) has recently become available in several
countries and can be performed under local anaesthesia with oral
or intravenous sedation; it can also be performed in men with blood
clotting disorders or in men receiving anticoagulant therapy and
therefore is being proposed and marketed  for men at high risk
of general anaesthesia (Chin 2012; Woo 2012). Typical inclusion
criteria for PUL include prostate volume between 20 mL and 70 mL,
IPSS of 12 or greater, measured Qmax of 15 mL/s or less, and PVR
of less than 350 mL (McNicholas 2016). The PUL system consists
of two single-use components (a delivery device and an implant).
The delivery device consists of a handheld pistol grip to which a
needle-shaped probe is attached. Each PUL implant consists of
a super-elastic nitinol capsular tab, a polyethylene terephthalate
monofilament, and a stainless steel urethral endpiece. The surgeon
inserts the probe into the urethra until it reaches the widest part
of the prostatic urethra; a fine needle at the end of the probe
then is deployed to secure an implant in a lobe of the prostate
(McNicholas 2016). One end of the implant is anchored in the
urethra, and the other is attached to the firm outer surface of
the prostatic capsule, thus pulling the prostatic lobe away from
the urethra. This is repeated on the other lobe of the prostate.
Systematically, four implants for PUL are delivered - two each to the
right and leM lateral lobes of the prostate (at the 2 o'clock and 10
o'clock positions, distally, from approximately 1.5 cm distal to the
bladder neck). PUL generally is not used to treat a hypertrophied
median lobe of the prostate, which causes obstructive intravesical
protrusion of the prostate (McNicholas 2016); however a recent
small observational study indicated that this might be feasible and
eFective (Rukstalis 2019). Mild adverse events, such as transient
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dysuria and haematuria, are commonly reported with PUL (Chin
2012; Woo 2012). Incontinence may be  less prevalent with PUL
(5%) than with TURP (11%) (NICE 2015). However, reoperation rates
appear to be higher with PUL (8%) than with TURP (6%) (NICE 2015).
In one feasibility study, implant encrustation occurred when PUL
implants were placed too close to the bladder and were exposed to
static urine (Chin 2012; Woo 2012).
Temporary implantable nitinol device
The temporary implantable nitinol device (TIND) labelled Medi-
Tate is a novel device that aims to provide prostatic patency.
This new minimally invasive procedure can be performed in an
outpatient setting under light sedation. The device is placed inside
the prostatic urethra via cystoscopy and is expanded upon release
(Porpiglia 2015), reshaping the bladder neck and the prostatic
urethra. No catheterisation is required. The 50-mm-long, 33-mm-
diameter device comprises three elongated struts and an anchoring
leaflet - all made of nitinol, a biocompatible super-elastic shape-
memory alloy (Porpiglia 2015). The device is removed 5 days
aMer placement in an outpatient setting under local anaesthesia
(lidocaine gel) with retraction via a cytoscope.
A single-arm multi-centre observational study with 32 participants
indicated that median IPSS scores decreased from 19 at baseline
to 10 at 3-week follow-up, and to 9 at 12-month follow-up. Four
patients suFered short-term complications (urinary incontinence,
urinary retention, urinary tract infection, and prostatic abscess)
(Porpiglia 2015). A 3-year follow-up indicated that IPSS scores
reached a median of 12 and no further complications were reported
(Porpiglia 2018).
A second-generation TIND device (iTIND) with structural diFerences
is currently available. Only three struts are used, and the upper
part of the device allows action exerted on the urethral mucosa
at the level of the bladder neck, with potential avoidance of
bladder mucosal injury (Bertolo 2018). A single-arm multi-centre
observational study evaluating iTIND on 81 participants indicated
that mean IPSS scores decreased from 22.5 ± 5.6 at baseline to
11.7 ± 8.0 at 1-month follow-up, and to 8.8 ± 6.4 at 12-month
follow-up. Only mild complications were reported: haematuria
(12.3%), micturition urgency (11.1%), pain (9.9%), dysuria (7.4%),
urinary tract infection (6.2%), and urinary retention (9.9%). Only
one participant required re-intervention in the form of TURP
(Porpiglia 2019). At least two ongoing randomised controlled trials
are evaluating this treatment (Bertolo 2018).
Transurethral microwave therapy
Transurethral microwave thermotherapy (TUMT) uses microwave-
induced heat to ablate prostatic tissue and is designed to have
fewer major complications than TURP (Walmsley 2004). The patient
is treated in an outpatient setting. Once the patient's bladder is
emptied by straight catheterisation, a local lidocaine gel is inserted
for local anaesthesia. The treatment catheter is then placed within
the urethra, and this is confirmed by return of the sterile water and
by transabdominal or transrectal ultrasound; then the balloon is
inflated. The catheter is composed of a curved tip, a temperature
sensor, and a microwave unit. The distal port contains the bladder
balloon, allowing for urine drainage and cooling. A rectal probe
may be inserted and can be used to monitor rectal temperature
(Rubeinstein 2003).
TUMT has evolved over past decades. The first systems worked
at lower energy or heat settings, and treatment would take
around an hour with minimal discomfort; however, results were
disappointing. Subsequent systems incorporated catheters that
provided urethral cooling, thus allowing higher energy delivery.
These advancements reduced the procedure time to around 30
minutes and improved outcomes. However, higher energy leads
to greater discomfort during the procedure, for which patients
oMen require sedation and analgesia, and presents risk for urinary
retention (EAU 2020; Walmsley 2004).
How the intervention might work
Convective radiofrequency water vapour therapy
Direct transfer of targeted and controlled convective thermal
energy doses to the transition zone of the prostate gland to treat
BPH by using sterile water vapour through tissue interstitial spaces
between cells releases its stored thermal energy to create apoptosis
and necrosis when in contact with hyperplastic prostatic tissue
(Aoun 2015). Reportedly, no thermal eFects are seen beyond the
confines of the prostate, thereby leaving the urethra, bladder
neck, and external sphincter unaFected (Aoun 2015; Woo 2017).
In comparison, conductive ablation therapy can cause necrosis of
surrounding tissues as higher temperatures and longer periods of
heating are required to achieve therapeutic eFects (Woo 2017).
Prostatic arterial embolisation
The underlying mechanism of PAE is the ischaemia or hypoxia that
induces apoptosis, necrosis, sclerosis, and prostatic shrinkage with
cystic transformation of part, or all, of the gland, resulting in a soMer
gland with reduced compression of the urethra (DeMeritt 2000; Sun
2008). In addition, PAE may decrease the plasma concentration
of free testosterone that enters prostate cells, thereby lowering
dihydrotestosterone levels in the prostate. This may result in the
secondary inhibition of prostate growth (Sun 2008). Furthermore,
ischaemia or hypoxia may induce prostate cell death and necrosis
with a decreased number of some receptors, such as alpha-
adrenergic receptors. Therefore, the neuromuscular tone may
decrease, resulting in improved clinical symptoms associated with
the dynamic pathological component of BPH (Zlotta 1997).
Prostatic urethral li5
The fundamental idea of PUL consists of separation and distraction
of enlarged prostatic tissue by a series of implants. The PUL system
uses adjustable, permanent implants to hold excess prostatic tissue
out of the way, thereby opening the narrowed urethra without
cutting or removing enlarged prostatic tissue (McNicholas 2016).
These implants are shaped as a double-ended hook and aim to
expand the opening of the urethra (McNicholas 2016).
Temporary implantable nitinol device
The fundamental principle of the TIND device involves 'reshaping'
the prostatic urethra and bladder neck, thereby reducing urinary
flow obstruction (Porpiglia 2015). This may be caused by the radial
force of sustained expansion of the TIND device, causing ischaemic
necrosis of the tissue and leading to bladder neck and prostatic
urethra incision.
Transurethral microwave therapy
TUMT uses a special transurethral catheter that transmits heat
into the prostate via electromagnetic radiation of microwaves,
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penetrating water-rich tissue. Energy transferred by the microwave
to the tissue in the form of heat induces coagulation necrosis,
reducing prostatic volume. This mechanism may also cause
denervation of receptors, decreasing the smooth muscle tone of
the prostatic urethra (Walmsley 2004). Temperatures lower than
45ºC seem ineFective in causing this eFect; therefore higher-energy
devices were developed to reach temperatures greater than 70ºC,
causing thermoablation of the prostatic tissue (Aoun 2015).
Why it is important to do this review
The Cochrane Urology Group has developed four reviews of studies
comparing each individual MIT to TURP and other therapies
(HoFman 2012; Jung 2017 (ongoing); Jung 2019; Kang 2020);
however, these reviews found few head-to-head comparisons.
HoFman 2012, the largest review, included several trials comparing
TUMT to TURP and sham procedures; Jung 2019 included two
trials - one comparing PUL to TURP and another one to sham; and
Kang 2020 included a single trial comparing CRFWVT to a sham
procedure. A recent systematic review and network meta-analysis
evaluated surgical therapies for BPH, but it covered only invasive
therapies such as diFerent forms of TURP and laser ablation
(Huang 2019). We found no systematic review and network meta-
analysis to date that has used the same rigorous methods used
in a Cochrane Review, which includes application of the GRADE
approach and focus on patient-important outcomes (Guyatt 2008).
A network meta-analysis could improve the precision of estimates
for each pair-wise comparison, create estimates for comparisons
for which no head-to-head trial was found, and provide ranking of
available interventions (Chaimani 2019). In contemporary practice,
with the availability of numerous MITs to treat BPH, the findings of
this Cochrane Review are expected to be relevant to policymakers,
healthcare providers, and patients.
O B J E C T I V E S
Primary
To assess the comparative eFectiveness of minimally invasive
treatments for lower urinary tract symptoms in men with benign
prostatic hyperplasia.
Secondary
To obtain an estimate of relative ranking of these minimally invasive
treatments according to their eFects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include parallel-group randomised controlled trials (RCTs)
only to avoid threatening the transitivity assumption. We will
exclude cross-over and cluster trials, as these study designs are not
relevant in this setting. We will exclude single-armed studies, quasi-
randomised trials, and observational studies. We will include RCTs
regardless of their publication status or language of publication.
Types of participants
We define the eligible patient population as men over the age of
40 years with a prostate volume of 20 mL or greater (as assessed
by DRE, ultrasound, and/or cross-sectional imaging) with LUTS, as
this can be determined by an IPSS of 8 or over and a Qmax less
than 15 mL/s, as measured by non-invasive uroflowmetry, invasive
pressure flow studies, or both (Dunphy 2015; EAU 2020; McNicholas
2016; McVary 2011). The age limitation is based on the observation
that the prevalence of BPH is increased in middle-aged and older
men, and that BPH is infrequent in younger men (Barry 1997; EAU
2020; Egan 2016). If these inclusion criteria are not fully described,
we will perform a sensitivity analysis (see Sensitivity analysis).
We will exclude trials of men with active urinary tract infection;
bacterial prostatitis; chronic renal failure; untreated bladder calculi
or large diverticula; prostate cancer; urethral stricture disease; or
prior prostate, bladder neck, or urethral surgery. We will exclude
studies of men with other conditions that aFect urinary symptoms,
such as neurogenic bladder due to spinal cord injury, multiple
sclerosis, or central nervous system disease.
We will assess the transitivity assumption by comparing
characteristics of participants and the distribution of potential
eFect modifiers, including age, prostate volume, and severity of
LUTS.
Types of interventions
We will include the following interventions.
Experimental interventions (decision set)
• Convective radiofrequency water vapour therapy (CRFWVT)
• Prostatic arterial embolisation (PAE)
• Prostatic urethral liM (PUL)
• Temporary implantable nitinol device (TIND)
• Transurethral microwave therapy (TUMT)
Comparator interventions (supplementary set)
• Sham control (or no intervention)
• TURP (monopolar or bipolar)
Comparisons
We will include trials comparing experimental interventions
versus comparator interventions or performing head-to-
head comparisons between experimental interventions (see
representation of the network in Figure 1). We will not include
the comparison TURP versus sham because our primary interest
is the comparative eFectiveness of minimally invasive treatments.
Participants in the network could in principle be randomised
to any of the methods being compared, and we will verify
this by comparing characteristics of study design, participants,
interventions, and comparisons (Salanti 2012), while considering
potential sources of clinical heterogeneity and eFect modification
(see Subgroup analysis and investigation of heterogeneity).
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Figure 1.   Network plot for minimal-invasive treatments. TURP: transurethral resection of the prostate; TUMT:
transurethral microwave thermotherapy of the prostate; TIND: temporary implantable nitinol device; PUL: prostatic
urethral li5; CRFWVT: convective radiofrequency water vapor; PAE: prostatic artery embolisation.
 
Types of outcome measures
We will not use measurement of the outcomes assessed in this
review as an eligibility criterion.
Primary outcomes
• Urological symptom scores
• Quality of life





• Minor adverse events
• Acute urinary retention
• Indwelling urinary catheter
Method and timing of outcome measurement
We will consider clinically important diFerences for all outcomes as
the basis for rating the certainty of evidence for imprecision in the
'Summary of findings' tables (Jaeschke 1989; Johnston 2013).
Urological symptom scores
• Mean change measured as IPSS (also known as the American
Urological Association Symptom Index) or other validated
scores (such as Madsen-Iversen symptom scores). The latter
would not be included in a network meta-analysis (see Measures
of treatment eFect)
• We will consider improvement in IPSS score of 3 points as a
minimal clinically important diFerence (MCID) to assess eFicacy
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and comparative eFectiveness (Barry 1995). If possible, we will
use diFerent thresholds of MCID based on the severity of IPSS,
with a threshold of 3 for mild LUTS, 5 for moderate LUTS, and 8
for severe LUTS (Barry 1995)
Quality of life
• Mean change measured as IPSS-quality of life
• No formal threshold was established for IPSS-quality of life.
We will use an MCID of 1 to assess eFicacy and comparative
eFectiveness (Brasure 2016; Rees 2015)
Major adverse events
• Examples include postoperative haemorrhage requiring
admission or intervention
• We will use the Clavien–Dindo classification system to assess
surgical complications and will categorise Grade III, IV, and V
complications as major (Dindo 2004)
• Based on Guyatt 2011a, we will consider a 25% relative change
as the threshold for a clinically important diFerence
Retreatment
• Events requiring other surgical treatment modalities (e.g. TURP)
aMer intervention. We will consider the first retreatment and will
account for repetitive events in a narrative synthesis
• Based on Guyatt 2011a, we will consider a 25% relative change
as the threshold for a clinically important diFerence
Erectile function
• Mean change, measured as total score on the International Index
of Erectile Function (IIEF)-5 questionnaire (also known as the
Sexual Health Inventory for Men) (Rosen 1997)
• We will consider a diFerence in IIEF-5 over 5 points as the MCID
(Spaliviero 2010)
Ejaculatory function
• Mean change, measured on the Male Sexual Health
Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD) (Rosen
2007)
• We will use an MCID of 25% improvement from baseline on the
MSHQ-EjD for ejaculatory function (Nickel 2015)
Minor adverse events
• Examples include postoperative fever or pain requiring
medication
• We will use the Clavien–Dindo classification system to assess
surgical complications and will categorise Grade I and II
complications as minor (Dindo 2004)
• Based on Guyatt 2011a, we will consider a 25% relative change
as the threshold for a clinically important diFerence
Acute urinary retention
• Events requiring catheterisation aMer intervention
• Based on Guyatt 2011a, we will consider a 25% relative change
as the threshold for a clinically important diFerence
Indwelling urinary catheter
• Proportion of participants with an indwelling catheter at
postoperative 24 hours
• Based on Guyatt 2011a, we will consider a 25% relative change
as the threshold for a clinically important diFerence
We will consider outcomes measured up to 12 months aMer
randomisation as short-term, and those later than 12 months
as long-term, for urological symptom scores, quality of life,
major adverse events, retreatment, erectile function, ejaculatory
function, minor adverse events, and acute urinary retention. We
will assess the indwelling urinary catheter over the short term only.
Main outcomes for 'Summary of findings' tables
We will present 'Summary of findings' tables reporting the
following outcomes listed according to priority.
• Urological symptom scores.
• Quality of life.




Search methods for identification of studies
We will perform a comprehensive search with no restrictions on
language of publication nor publication status.
Electronic searches
We will retrieve relevant studies from existing Cochrane Reviews for
each individual treatment (HoFman 2012; Jung 2017; Jung 2019;
Kang 2020). We will update searches for each of the individual
Cochrane Reviews assessing each minimally invasive treatment.
We will perform a comprehensive search for TIND from the
inception of each of the following databases (see Appendix 1).
• Cochrane Library via Wiley.
* Cochrane Database of Systematic Reviews.
* Cochrane Central Register of Controlled Trials.
* Database of Abstracts of Reviews of EFects.
* Health Technology Assessment Database.
• MEDLINE via Ovid (from 1946).
• Embase via Elsevier (from 1974).
• Scopus (from 1966).
• Web of Science (from 1900).
• Latin American and the Caribbean Health Sciences Literature
(LILACS; www.bireme.br/, from 1982).
We will also search the following.
• ClinicalTrials.gov (www.clinicaltrials.gov/).
• World Health Organization (WHO) International Clinical Trials
Registry Platform search portal (apps.who.int/trialsearch/).
• Grey literature repository from the current Grey Literature
Report (www.greylit.org/).
Searching other resources
We will try to identify other potentially eligible trials and ancillary
publications by searching the reference lists of retrieved included
trials, reviews, meta-analyses, and health technology assessment
reports. We will contact study authors of included trials to identify
further studies that we may have missed. We will contact drug/
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device manufacturers for ongoing or unpublished trials. We will
search abstract proceedings of relevant meetings of the American
Urological Association, the European Association of Urology,
and the International Continence Society for 2017 to 2020 for
unpublished studies.
Data collection and analysis
Selection of studies
We will use EndNote 2016 reference management soMware to
identify and remove potential duplicate records. Two review
authors (JVAF, LG) will independently scan abstracts, titles, or
both to determine which studies should be assessed further
using Covidence 2013 soMware. Two review authors (of JVAF,
LG, JHJ, MI, and MIO) will investigate all potentially relevant
records as full text, will map records to studies, and will classify
studies as included studies, excluded studies, studies awaiting
classification, or ongoing studies in accordance with the criteria for
each provided in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2019). We will resolve any discrepancies
through consensus or recourse to a third review author (PD). We
will document reasons for exclusion. We will present an adapted
PRISMA flow diagram showing the process of study selection
(Liberati 2009).
Data extraction and management
We will develop a dedicated data abstraction form that we will pilot-
test ahead of time. Because we will retrieve relevant studies from
existing Cochrane Reviews for each individual treatment for which
study characteristics, outcome data, and risk of bias assessments
were done by members of our review team (HoFman 2012; Jung
2017; Jung 2019; Kang 2020), the following sections will apply only
to new studies identified by our search methods.
For studies that fulfilled inclusion criteria, two review authors




• Study settings and country.
• Participant inclusion and exclusion criteria (e.g. age, baseline
IPSS).
• Participant details, baseline demographics (e.g. age, prostate
size, IPSS).
• Numbers of participants by study and by study arm.
• Details of relevant experimental intervention (e.g. size of
cystoscope, energy-generating device, embolisation agent,
delivery device) and comparator intervention (e.g. monopolar
versus bipolar energy, specifications of the sham procedure).
• Definitions of relevant outcomes and methods (e.g. type of
instrument, such as IPSS) and timing of outcome measurement
(e.g. in months), as well as relevant subgroups (e.g. based on
age, prostate volume, severity of LUTS).
• Study funding sources.
• Declarations of interest by primary investigators.
We will extract outcome data relevant to this Cochrane Review
as needed for calculation of summary statistics and measures of
variance. For dichotomous outcomes, we will present numbers of
events and totals for populations in a 2 × 2 table, as well as summary
statistics with corresponding measures of variance. For continuous
outcomes, we will obtain means and standard deviations or data
necessary to calculate this information.
We will resolve any disagreements by discussion or, if required, by
consultation with a third review author (PD).
We will provide in tables information, including the trial identifier,
about potentially relevant studies.
We will contact authors of included studies to obtain key missing
data as needed.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents, or
multiple reports of a primary study, we will maximise yield of
information by mapping all publications to unique studies and
collating all available data. We will use the most complete data
set aggregated across all known publications. In case of doubt, we
will give priority to the publication reporting the longest follow-up
associated with our primary or secondary outcomes.
Assessment of risk of bias in included studies
Two review authors (JVAF and LG) will independently assess the
risk of bias of each included study. We will resolve disagreements
by consensus, or by consultation with a third review author (PD).
We will present a 'Risk of bias' summary figure to illustrate these
findings. We will further summarise the risk of bias across domains
for each outcome in each included study, as well as across studies
and domains, for each outcome in accordance with the approach
for summary assessments of risk of bias presented in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Assessment of risk of bias in randomised controlled trials
We will assess risk of bias using Cochrane's 'Risk of bias' assessment
tool (Higgins 2011). We will assess the following domains.
• Random sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding of participants and personnel (performance bias).
• Blinding of outcome assessment (detection bias).
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Other sources of bias.
We will judge risk of bias domains as 'low risk', 'high risk', or 'unclear
risk' and will evaluate individual bias items as described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).
For selection bias (random sequence generation and allocation
concealment), we will evaluate risk of bias at a trial level.
For performance bias (blinding of participants and personnel), we
will consider all outcomes similarly susceptible to performance
bias.
For detection bias (blinding of outcome assessment), we will group
outcomes as susceptible to detection bias (subjective) or not
susceptible to detection bias (objective) outcomes.
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We define the following endpoints as subjective outcomes.
• Urological symptom scores.
• Quality of life.
• Major adverse events.
• Erectile function.
• Ejaculatory function.
• Minor adverse events.
We define the following endpoints as objective outcomes.
• Retreatment.
• Acute urinary retention.
• Indwelling urinary catheter.
We will assess attrition bias (incomplete outcome data) on an
outcome-specific basis and will present the judgement for each
outcome separately when reporting our findings in 'Risk of bias'
tables.
For reporting bias (selective reporting), we will evaluate risk of bias
at a trial level.
Measures of treatment eBect
Relative treatment e#ect
We will express dichotomous data as risk ratios (RRs) with 95%
confidence interval (CIs) to enhance the interpretability of results.
We will express continuous data as mean diFerences (MDs) with
95% CIs. We will prioritise post-intervention over change from
baseline measurements. We anticipate that diFerent scales might
be used for urological symptom scores (e.g. Madsen symptom score
in few older studies), in which case we will include outcome data
using the preferred scale for this outcome (i.e. IPSS) and will report
outcome data from other scales separately in a narrative synthesis
of quantitative data. In the presence of binary and continuous data
for the same outcome, we will perform analysis for continuous data,
and if suFicient data are available for each comparison, we will
perform analysis for binary data.
Relative treatment ranking
We will obtain a treatment hierarchy using P scores (Rücker 2015).
P scores allow ranking of treatments on a continuous zero to 1 scale
in a frequentist framework network meta-analysis.
Unit of analysis issues
The unit of analysis will be the individual participant. When
multiple trial arms are reported in a single trial, we will include only
the arms with comparisons relevant to the network (see Figure 1).
Dealing with missing data
We will obtain missing data (e.g. missing standard deviation) from
study authors and will perform intention-to-treat analyses if data
are available. We will investigate attrition rates (e.g. dropouts,
losses to follow-up, withdrawals) and will critically appraise issues
of missing data. We will not impute missing data.
Assessment of heterogeneity
Pair-wise meta-analysis
We will identify heterogeneity through visual inspection of forest
plots to assess the amount of overlap of CIs and the I2 statistic,
which quantifies between-study variation across studies, to assess
the impact of heterogeneity on the meta-analysis (Higgins 2002;
Higgins 2003). We will interpret the I2 statistic as follows (Deeks
2011).
• 0% to 40%: may not be important.
• 30% to 60%: may indicate moderate heterogeneity.
• 50% to 90%: may indicate substantial heterogeneity.
• 75% to 100%: considerable heterogeneity.
We will also use Cochran’s Q test to assess for heterogeneity of
estimated eFect sizes from individual studies. However, we will
cautiously interpret these results considering both the low power
to detect true heterogeneity when the number of studies is small,
and the excessive power needed to detect negligible heterogeneity
when the number of studies is high (Huedo-Medina 2006; Pereira
2010).
Network meta-analysis
Assessment of the transitivity assumption
Before conducting a network meta-analysis, we will assess
the transitivity assumption. Network meta-analysis rests on the
assumption of transitivity, that is, that eFect modifiers have
a comparable distribution across treatment comparisons in a
network (Cipriani 2013; Jansen 2013). To assess the plausibility
of this assumption, we will visually inspect the comparability of
distributions of age, prostate volume, and urological symptom
score severity (IPSS), time point of outcome assessment, and risk of
bias (randomisation, allocation concealment, and blinding to risk
of bias) as potential treatment eFect modifiers across comparisons
(Salanti 2014). We will assess the similarity of inclusion and
exclusion criteria of all studies, including participants, treatments,
and outcomes, to evaluate whether they impact treatment eFects.
Assessment of statistical consistency
Lack of transitivity in a network can threaten the validity of the
consistency assumption, that is, statistical agreement between
direct and indirect evidence (Caldwell 2005; Lu 2004). Results can
be misleading in the presence of inconsistency in the network.
We will evaluate the presence of inconsistency both locally and
globally. We will evaluate each network locally using the loop-
specific method by generating an inconsistency factor along with
a 95% CI for each closed loop (Veroniki 2013). This way, we
will identify which piece of evidence will be responsible for
inconsistency, and we will explore this further. We will also apply
a global assessment for consistency in each network by applying
the design-by-treatment interaction model (White 2012a). It has
been shown that inconsistency tests have low power to detect true
inconsistency (Song 2012; Veroniki 2014). Hence, we will assess
transitivity even in the absence of evidence for inconsistency. If
inconsistency is found, we will follow the guidance provided in
the Cochrane Handbook for Systematic Reviews of Interventions
(Section 11.4.4.4; Chaimani 2019).
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Assessment of reporting biases
We will attempt to obtain study protocols to assess for selective
outcome reporting.
We will use comparison-adjusted funnel plots to assess small-study
eFects (Chaimani 2013). Several explanations can be oFered for
the asymmetry of a funnel plot, including true heterogeneity of
eFect with respect to trial size, poor methodological design (and
hence bias of small trials), and publication bias. We will, therefore,
interpret results carefully.
Data synthesis
Methods for direct treatment comparisons
We will perform analyses according to recommendations provided
in Chapter 9 of the Cochrane Handbook for Systematic Reviews
of Interventions (Deeks 2011), and we will use the statistical
soMware of Cochrane - Review Manager 2014 - for analysis.
If appropriate, we will perform these standard pair-wise meta-
analyses using a random-eFects model because we anticipate
methodological and clinical heterogeneity across studies. We will
calculate corresponding 95% CIs for all analyses, and we will
graphically present the results using forest plots. When trials are
clinically too heterogeneous to be combined, we will perform only
subgroup analyses without calculating an overall estimate.
Methods for indirect and network comparisons
We will fit a random-eFects network meta-analysis model because
we anticipate methodological and clinical heterogeneity across
studies. We will assume a common within-network heterogeneity
estimate across comparisons, and we will estimate this using the
restricted maximum likelihood (REML) method (Veroniki 2016). This
is a reasonable assumption given that all treatments included in
the network are of the same nature. An advantage of this approach
is that treatment comparisons informed by a single study can
borrow strength from the rest of the studies in the network (Higgins
1996; Salanti 2008). Each network meta-analysis treatment eFect
estimate will be presented along with a 95% CI and a 95% predictive
interval (PrI). A PrI is an interval within which the treatment eFect
estimate of a future study is expected to lie, accounting for both
uncertainty of the treatment eFect and between-study variance
estimates (Higgins 2009; Riley 2011). We will conduct network
meta-analysis by using the network suite of commands in Stata
(White 2012; White 2015).
Relative treatment ranking
We will estimate the ranking probabilities that all treatments will be
at each possible rank for each intervention. We will use the surface
under the cumulative ranking (SUCRA) curve to rank eFectiveness
and safety of minimally invasive interventions (Salanti 2011).
SUCRA accounts for both eFect size magnitude and uncertainty
around the underlying eFect size. We will use the rank-heat plot
to present SUCRA values for all outcomes in a single plot (Veroniki
2016). We will display (network plot and league table) results using
the 'network graph package' in Stata (Chaimani 2015).
Subgroup analysis and investigation of heterogeneity
When we find important heterogeneity and/or inconsistency, we
will explore possible sources for primary outcomes. When suFicient
studies are available, we will perform subgroup analysis by using
the following potential eFect modifiers as possible sources of
inconsistency and/or heterogeneity.
• Patient age (younger than 65 years versus 65 years and older).
• Prostate volume (≤ 40 mL or > 40 mL).
• Severity of LUTS based on IPSS (score ≤ 19 (moderately
symptomatic) versus > 19 (severely symptomatic)).
These subgroup analyses are based on the following observations.
• Age is a well-known risk factor for BPH surgery. Older people
have a higher rate of postoperative complications compared
with younger people (Bhojani 2014; Pariser 2015). The age cut-
oF is based on the World Health Organization (WHO) definition
of old age (WHO 2002).
• Outcomes and complications of minimally invasive procedures,
such as TURP, correlate with prostate volume (Reich 2008).
Prostate volume cut-oF greater than 40 mL is based on this being
the most commonly used threshold to distinguish 'small' from
'large' for the indication of treatment with a 5-alpha reductase
inhibitor (EAU 2020).
• The relationship between changes in IPSS scores and patient
global ratings of improvement is influenced by baseline scores
(Barry 1995).
We plan to perform subgroup analyses limited to the primary
outcomes.
Sensitivity analysis
We plan to perform sensitivity analyses limited to the primary
outcomes to explore the influence of the following factors (when
applicable) on eFect size.
• Restricting the analysis in RCTs by taking into account risk of
bias, by excluding studies at 'high risk' or 'unclear risk' (studies
with at least one domain at 'high risk' or 'unclear risk' of bias for
the analysed outcome).
• Restricting the analysis to RCTs with adequately described
inclusion criteria (prostate size, age, IPSS value, and Qmax).
'Summary of findings' tables
We will use 'Summary of findings' (SoF) tables to summarise
key results of the Review, using the Confidence in Network
Meta-analysis (CINeMA) framework and soMware (Chaimani 2019;
CINEMA 2017; Salanti 2014). We will include the following
outcomes.
• Urological symptom scores.
• Quality of life.




We will use the five GRADE criteria (study limitations, consistency of
eFect, imprecision, indirectness, and publication bias) to evaluate
the quality of a body of evidence as it relates to studies that
contributed data to the meta-analysis for each pre-specified
outcome (Guyatt 2008). Two review authors (JVAF and LG) will
independently make judgements about quality of the evidence
(high, moderate, low, or very low) and will resolve disagreements by
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discussion or consultation with a third review author (PD). We will
create an SoF table for each outcome using the approach presented
by Yepes-Nuñez 2019 (see Table 1 and Table 2).
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Comparator (reference): sham procedure
Outcome:
Setting: hospital procedure – outpatient follow-up
(network plot on the right) *
Total studies
Total participants















MIT 1            
MIT 2            
MIT 3            
MIT 4            
MIT 5            
TURP            
Sham procedure            
MIT: minimally invasive treatment, CI: confidence interval.
Network meta-analysis summary of findings table definitions.
* Lines in the network graphic represent direct comparisons.
Table 1.   Dummy summary of findings table (dichotomous outcomes) 
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** Estimates are reported as odds ratio and CI.
*** Anticipated absolute effect compares two risks by calculating the difference between risks of the intervention group and risk of
the control group.
**** Ranking and confidence intervals for efficacy outcomes are presented. Rank statistics is defined as the probability that a treat-
ment out of n treatments in a network meta-analysis is the best, the second, the third, and so on until the least effective treatment.
GRADE Working Group grades of evidence (or certainty of the evidence).
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Explanatory footnotes






Comparator (reference): sham procedure
Outcome:
Setting: hospital procedure – outpatient follow-up
(network plot on the right) *
Total studies
Total participants
  Anticipated absolute effect (95% CI) **
  Relative
effect







MIT 1          
MIT 2          
MIT 3          
MIT 4          
MIT 5          
TURP          
Table 2.   Dummy summary of findings table (continuous outcomes) 
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SHAM          
MIT: minimally invasive treatment, CI: confidence interval.
Network meta-analysis summary of findings table definitions.
* Lines in the network graphic represent direct comparisons.
** Estimates are reported as mean difference and confidence interval (CI).
*** Ranking and confidence intervals for efficacy outcome are presented. Rank statistics is defined as the probability that a treatment
out of n treatments in a network meta-analysis is the best, the second, the third, and so on until the least effective treatment.
GRADE Working Group grades of evidence (or certainty of the evidence).
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Explanatory footnotes
Table 2.   Dummy summary of findings table (continuous outcomes)  (Continued)
 
 
A P P E N D I C E S
Appendix 1. Search strategy
 
Cochrane Library (via Wiley)
#1 MeSH descriptor: [Prostatic Hyperplasia] explode all tree
#2 MeSH descriptor: [Prostatism] explode all trees
#3 MeSH descriptor: [Urinary Bladder Neck Obstruction] explode all trees
#4 (Prostat* near/3 hyperplasia*):ti,ab,kw
#5 (Prostat* near/3 hypertroph*):ti,ab,kw
#6 (Prostat* near/3 adenoma*):ti,ab,kw
#7 (BPH OR BPO OR BPE):ti,ab,kw
#8 (prostat* near/3 enlarg*):ti,ab,kw
#9 (Prostatism):ti,ab,kw
#10 (Bladder* near/3 obstruct*):ti,ab,kw
#11 (BOO):ti,ab,kw




#16 #13 OR #14 OR #15
#17 #12 AND #16
MEDLINE (via Ovid)
#1 exp Prostatic Hyperplasia/
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#2 exp Prostatism/
#3 exp Urinary Bladder Neck Obstruction/
#4 (Prostat* adj3 hyperplasia*).tw.
#5 (Prostat* adj3 hypertroph*).tw.
#6 (Prostat* adj3 adenoma*).tw.
#7 (BPH or BPO or BPE).tw.
#8 (prostat* adj3 enlarg*).tw.
#9 Prostatism.tw.(590)
#10 (Bladder* adj3 obstruct*).tw.
#11 BOO.tw.




#16 #13 OR #14 OR #15





#4. (prostat* NEAR/3 hyperplasia*):ti,ab,kw
#5. (prostat* NEAR/3 hypertroph*):ti,ab,kw
#6. (prostat* NEAR/3 adenoma*):ti,ab,kw
#7. bph:ti,ab,kw OR bpo:ti,ab,kw OR bpe:ti,ab,kw
#8. (prostat* NEAR/3 enlarg*):ti,ab,kw
#9. prostatism:kw,ti,ab
#10. (bladder* NEAR/3 obstruct*):ti,ab,kw
#11. boo:ti,ab,kw





#17. #13 OR #14 OR #15 OR #16
#18. #12 AND #17
LILACS
tw:(“prostatic hyperplasia” OR “hiperplasia prostática” OR prostat* OR “urinary bladder neck obstruction” OR “obstrucción del cuel-
lo de la vejiga urinaria” OR “obstrução do colo da bexiga urinária” OR bph OR bpo OR bpe) AND tw:(Nitinol OR TIND OR DNIT)
Scopus
TITLE-ABS-KEY ( "Prostatic Hyperplasia" OR prostat* OR "Urinary Bladder Neck Obstruction" ) AND TITLE-ABS-KEY ( nitinol OR tind
OR itind )
  (Continued)
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Web of Science
#1 TI=("Prostatic Hyperplasia" OR Prostat* OR "Urinary Bladder Neck Obstruction")
#2 TS=("Prostatic Hyperplasia" OR Prostat* OR "Urinary Bladder Neck Obstruction")
#3 #1 OR #2
#4 TS=(nitinol OR tind OR itind ) OR TI=( nitinol OR tind OR itind)
#5 #4 AND #3
  (Continued)
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N O T E S
We based portions of the Methods section of this review on a standard template developed by the Cochrane Metabolic and Endocrine
Disorders Group, which was modified and adapted for use by Cochrane Urology. General concepts of benign prostatic hyperplasia and
review methods has been adapted from one of the reviews from the suite on this topic (HoFman 2012; Jung 2017; Jung 2019; Kang 2020).
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